Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eliXCfbwocfCpFABfzWO

February 22, 2013
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  • Valeant pays $65M upfront for U.S. rights to Eisai's Targretin
    Eisai has sold the U.S. rights to Targretin capsules and 1% gel to Valeant Pharmaceuticals for $65 million plus possible milestone fees. Valeant will handle the new drug application and other regulatory obligations in the U.S. Targretin, or bexarotene, capsules and gel are used to treat patients with skin problems associated with cutaneous T-cell lymphoma who failed to respond to at least one systemic treatment. Genetic Engineering & Biotechnology News (2/21) LinkedInFacebookTwitterEmail this Story
Is Pricing Low Your Strategy to Success? Think again.
Pricing is the heart of a business. It affects everything you do and is affected by everything you do. Economists talk of supply and demand as key factors behind pricing—successful entrepreneurs manipulate demand by making their products more desirable. These six steps will help you determine the right price for your product or service, read the article and learn how to get pricing right.

  Health Care & Policy 
 
  • Pluristem gets orphan drug designation for PLacental eXpanded cells
    Pluristem Therapeutics' PLacental eXpanded cells have been designated an orphan-disease treatment by the FDA as a therapy for aplastic anemia. "Receiving orphan drug designation for aplastic anemia is an important event for Pluristem as it open pathways for using our PLX cells for additional indications in the field of hematology," said Zami Aberman, Pluristem's chairman and CEO. Globes (Israel) (2/21) LinkedInFacebookTwitterEmail this Story
Clinical Trial Data Transparency Forum: Expert insights
Hear industry and academic thought leaders - from Duke Clinical Research Institute, GlaxoSmithKline, Eli Lilly and more - share valuable insight on their clinical trial data transparency and sharing initiatives. This video covers a number of key perspectives and trends.

  Company & Financial News 
  • Eurofins boosts genomics business with Aros buy
    Aros Applied Biotechnology, a Denmark-based provider of sequencing and other genomics services, has been acquired by Eurofins Scientific. The deal will bolster Eurofins' presence in the sequencing market. "Aros is an excellent strategic fit with Eurofins' genomic services business," Eurofins chief executive Gilles Martin said. GenomeWeb Daily News (free registration) (2/21) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  Industrial & Environmental 
  • N.D. researchers tout biofuel potential of energy beets
    Scientists at Northern Great Plains Research Laboratory in North Dakota say trials have shown energy beets grown on an acre of non-irrigated land doubles the amount of ethanol produced by corn on a comparable basis, and that figure increases on irrigated land. BeetsAll Biofuel, a partner in the project, aims to develop 16 energy beet processing facilities in North Dakota, with the first due to break ground in 2015, a company representative said. The Bismarck Tribune (N.D.) (2/21) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
You can do anything in this world if you are prepared to take the consequences."
--W. Somerset Maugham,
British writer


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information